- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05575037
Mekanismer for fordel ved IL4RA-hemming ved aspirinforverret luftveissykdom (MARINER)
Mekanismer for fordel ved IL4RA-hemming ved aspirinforverret luftveissykdom: MARINER
The overall aim of the study is to determine the clinical efficacy and mechanisms of action of anti-IL-4a (dupilumab) as treatment for patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Aspirin-Exacerbated Respiratory Disease (AERD).
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The protocol involves an 8-week study of dupilumab in patients with CRSwNP and/or AERD. Participants will have 4 total doses of dupilumab administered, with each dose administered every 2 weeks. There will be full clinical assessments and biospecimen collections at Baseline (Visit 1), Week 2 (Visit 2), and Week 8 (Visit 3).
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Brigham and Women's Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
-
History of AERD, defined as meeting the diagnostic triad with:
- History of physician-diagnosed asthma and
- History of physician-diagnosed nasal polyposis and
- History of pathognomonic reactions to aspirin or other nonselective COX inhibitors.
-
Visible nasal polyps bilaterally on otoscope physical exam at the time of screening.
-
Evidence of sense of smell impairment, with a University of Pennsylvania Smell Identification Test (UPSIT) score of <34.
-
Stable asthma (no glucocorticoid burst for at least 4 weeks prior to Visit 1, and no hospitalizations or ER visits for asthma for at least the prior 3 months).
-
Consistent (daily) use of an intranasal steroid for at least 4 weeks prior to Screening.
-
No current smoking (not more than one instance of smoking in the last 3 months).
-
For females: Practicing FDA-approved methods of birth control for the duration of the study. Female participants of childbearing potential must have a negative pregnancy test upon study entry.
Key Exclusion Criteria:
- Use of investigational drugs within 12 weeks of Screening.
- Use of any biologic agent within 4 months prior to Screening.
- Use of systemic (enteral or injected) glucocorticoids within 4 weeks prior to Screening.
- History of any sinonasal surgery within 4 months prior to Screening
- Current use of zileuton
- Current use of high-dose aspirin therapy (no more than 325 mg aspirin per day will be allowed)
- Pregnant, nursing, or planning to become pregnant
Note: Other inclusion and exclusion criteria apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Dupilumab
Subjects will receive dupilumab (300mg every-other-week for 8 weeks). |
8-week trial of dupilumab (an anti-IL-4a) in patients with AERD.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Nasal Fluid Levels of LTE4
Tidsramme: At Week 8 (Visit 3)
|
The nasal fluid levels of LTE4 will be measured at week 8 and will serve as a surrogate biomarker of respiratory mast cell activation or burden. |
At Week 8 (Visit 3)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Nasal Fluid Levels of Albumin
Tidsramme: At Week 8 (Visit 3)
|
The nasal fluid levels of albumin will be measured at week 8 and serve as a surrogate biomarker of nasal epithelial cell integrity. |
At Week 8 (Visit 3)
|
|
Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)
Tidsramme: At Week 8 (Visit 3)
|
Patients' sense of smell will be assessed at week 8 using the UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified) |
At Week 8 (Visit 3)
|
|
Rhinoscopic Total Polyp Score (TPS)
Tidsramme: At Week 8 (Visit 3)
|
The extent of patients' nasal polyps will be assessed at week 8 using a TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst. |
At Week 8 (Visit 3)
|
|
Peak Nasal Inspiratory Flow (PNIF)
Tidsramme: At Week 8 (Visit 3)
|
Patients' nasal congestion will be assessed at week 8 by a PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst. |
At Week 8 (Visit 3)
|
|
Quality of Life - 22-Item Sino-Nasal Outcome Test (SNOT-22)
Tidsramme: At Week 8 (Visit 3)
|
Quality of life will be assessed at week 8 with a SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control). |
At Week 8 (Visit 3)
|
|
Lung Function - Forced Expiratory Volume 1 (FEV1)
Tidsramme: At Week 8 (Visit 3)
|
Patients' lung function will be assessed at week 8 with an FEV1. |
At Week 8 (Visit 3)
|
|
Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)
Tidsramme: At Week 8 (Visit 3)
|
Asthma control will be measured at week 8 with an ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control. |
At Week 8 (Visit 3)
|
|
Number of Treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs) Leading to Study Drug Discontinuation
Tidsramme: At Week 8 (Visit 3)
|
Safety will be measured by the number of treatment-related AEs and SAEs leading to dupilumab discontinuation. |
At Week 8 (Visit 3)
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)
Tidsramme: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified) |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Rhinoscopic Total Polyp Score (TPS)
Tidsramme: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Peak Nasal Inspiratory Flow (PNIF)
Tidsramme: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in 22-Item Sino-Nasal Outcome Test (SNOT-22)
Tidsramme: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control). |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Lung Function - Forced Expiratory Volume 1 (FEV1)
Tidsramme: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in FEV1. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)
Tidsramme: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Nasal Fluid Levels of Eicosanoids
Tidsramme: weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid eicosanoid levels. |
weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Nasal Fluid Levels of Albumin
Tidsramme: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid albumin levels. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Urinary Levels of Eicosanoids
Tidsramme: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in urinary eicosanoid levels. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Serum Tryptase
Tidsramme: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in serum tryptase levels. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in IgE Levels
Tidsramme: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid and plasma levels of IgE. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Eosinophilic Cationic Protein (ECP)
Tidsramme: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid levels of ECP. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Tanya M Laidlaw, MD, Brigham and Women's Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Patologiske tilstander, anatomiske
- Sykdommer i immunsystemet
- Sykdommer i luftveiene
- Bronkiale sykdommer
- Respiratorisk overfølsomhet
- Overfølsomhet, Umiddelbar
- Overfølsomhet
- Kjemisk-induserte lidelser
- Nesesykdommer
- Otorhinolaryngologiske sykdommer
- Legemiddelrelaterte bivirkninger og uønskede reaksjoner
- Polypper
- Medikamentoverfølsomhet
- Astma
- Patologiske tilstander, tegn og symptomer
- Nesepolypper
- Astma, Aspirin-indusert
- dupilumab
Andre studie-ID-numre
- 2022P002407
- U19AI095219 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .